Photo: Joe Raedle / Getty Images
The Modern COVID vaccine immunity – 19 lasts at least six months , and there is no indication that fully vaccinated people need a booster vaccine, according to a study published Tuesday by Science .
The vaccine also appears to produce long-lasting protection against coronavirus in people of all ages, including those of 70 years or more than are at increased risk of severe disease, according to research.
“Immune memory was stable, and that was impressive,” said co-author Shane Crotty in a press release .
)
“That is a good indicator of the durability ”of the Moderna and Pfizer-BioNTech vaccines, which are manufactured with formulations Similar said Crotty, a professor of vaccine research at the La Jolla Institute.
Findings are based on an analysis of 35 enrolled in early clinical trials of the vaccine, who received a low-dose version that equates to a quarter of the dose of 100 micrograms being given now, the researchers said.
“We wanted to see if a quarter of the dose is capable of inducing an immune response,” said study co-author José Mateus Triviño in a press release.
“We had the opportunity to receive the original samples… Phase 1 trial participants who had received two injections of 25 micrograms of vaccine, with 28 days of difference, “said Mateus Triviño, postdoctoral fellow at the La Jo Institute. lla in California.
Clinical trials conducted with patients who received the full dose of Moderna’s vaccine found that the injection offered protection from 93% against serious illnesses for at least six months, according to data published by the company.
Although Moderna’s vaccine, as well as those from Johnson & Johnson and Pfizer-BioNTech, reduce the risk of serious diseases, even with the most dangerous Delta variant , may be less effective and immunity could begin to weaken in as little as four months, studies show.
For this study, the researchers from the La Jolla Institute compared immunity in recovered COVID patients – 11 with that of vaccine trial participants who received a dose of 25 micrograms of Moderna vaccine during clinical trials s of Phase 1.
This dose is a quarter of the dose of 100 micrograms of Moderna given emergency authorization by the Food and Drug Administration in December of last year.
Most of the 35 patients included in the analysis continued to have high antibody responses six months after being fully vaccinated, according to the researchers.
Antibodies are cells produced by the immune system to fight viruses.
This six-month period is enough for the body to produce “immune memory” against COVID – 19, which means that the protection offered by the vaccine could last much longer, the researchers said.
This suggests that the vac Booster shots, which have been a source of controversy given dose shortages in some parts of the world, may not be necessary with Moderna, particularly at the full dose, they said.
Additionally, the researchers found that Moderna’s vaccine stimulates an adaptive immune response to the virus that is nearly identical to the natural response to infection.
Also seems to increase the response immune created by the common cold, which is also caused by a coronavirus, further strengthening protection, according to the researchers.
However, the The study did not show that a lower dose of Moderna’s vaccine provides the same protection as the standard dose, as doing so would require a clinical trial.
Read more
Unvaccinated in the US have 11 times more likely to die if infected, according to CDC
Biden Announces COVID Vaccine Mandates – millions of Americans
Health Officials Recommend COVID Booster Shots – 19 for all Americans